AKEBIA THERAPEUTICS ANNOUNCES INITIATION OF A PHASE 2 BASKET TRIAL TO STUDY EBRIBAFUSP, A NEXT-GENERATION COMPLEMENT INHIBITOR IN RARE KIDNEY DISEASES

Reuters · 2d ago

Please log in to view news